Of particular clinical relevance, the spatial distribution and quantitative expression of PD-1/PD-L1 within both tumor parenchyma and infiltrating immune cells have gained recognition as predictive biomarkers for patient outcomes in contemporary oncology. This evidence concerns the gene PDCD1 and neoplasm.